TransMedics Group WKN: A2PH5P ISIN: US89377M1099 Kürzel: TMDX Forum: Aktien Thema: Hauptdiskussion

TransMedics: Aircraft Additions Bring Immense Gross-Value Add, Reiterate Buy https://seekingalpha.com/article/4625251-transmedics-aircraft-additions-immense-gross-value-add Summary • TransMedics Group, Inc. posted exceptional Q2 results with a 156% YoY increase in revenues, reaching the highest second-quarter turnover in the company's history. • The company aims to have 100% availability over the U.S. continent by mid-next year, with plans to acquire 10-15 aircrafts for its air logistics operations. • Net-net, reiterate buy, revising the price objective to $150/share. ...

Ouch, bin wieder drin

https://www.prnewswire.com/news-releases/transmedics-reports-second-quarter-2023-financial-results-301893091.html

https://www.prnewswire.com/news-releases/transmedics-acquires-warm-perfusion-evoss-and-cold-perfusion-lifecradle-technologies-from-bridge-to-life-301892032.html

https://www.prnewswire.com/news-releases/transmedics-signs-definitive-agreement-to-acquire-summit-aviation-to-expand-transmedics-aviation-capabilities-for-organ-transplantation-301890528.html

TransMedics Reports First Quarter 2023 Financial Results https://finance.yahoo.com/news/transmedics-reports-first-quarter-2023-200500397.html

🍀

TransMedics Group Q4 EPS $(0.21) Beats $(0.30) Estimate, Sales $31.38M Beat $24.45M Estimate https://www.benzinga.com/news/earnings/23/02/31017364/transmedics-group-q4-eps-0-21-beats-0-30-estimate-sales-31-38m-beat-24-45m-estimate TransMedics Group (NASDAQ:TMDX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.30) by 30 percent. This is a 54.35 percent increase over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $31.38 million which beat the analyst consensus estimate of $24.45 million by 28.32 percent. This is a 224.52 percent increase over sales of $9.67 million the same period last year.

https://seekingalpha.com/news/3939484-transmedics-q4-results-beat-estimates-co-sees-fy-2023-revenue-above-consensus TransMedics Q4 results beat estimates, co sees FY 2023 revenue above consensus • TransMedics Group press release (NASDAQ:TMDX): Q4 GAAP EPS of -$0.21 beats by $0.11. • Revenue of $31.4M (+223.7% Y/Y) beats by $7.8M. • Expects total revenue for full-year 2023 to be in the range of $138 million to $145 million. The consensus estimate is $134.66M. 

TransMedics Reports Fourth Quarter and Full Year 2022 Financial Results https://www.prnewswire.com/news-releases/transmedics-reports-fourth-quarter-and-full-year-2022-financial-results-301753645.html

https://www.prnewswire.com/news-releases/transmedics-appoints-nick-corcoran-as-senior-vice-president-of-supply-chain-and-operations-301737904.html

https://www.prnewswire.com/news-releases/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301670734.html

🍀

TransMedics Group GAAP EPS of -$0.25 beats by $0.15, revenue of $25.7M beats by $6.82M https://seekingalpha.com/news/3901375-transmedics-group-gaap-eps-of-0_25-beats-0_15-revenue-of-25_7m-beats-6_82m • TransMedics Group press release (NASDAQ:TMDX): Q3 GAAP EPS of -$0.25 beats by $0.15. • Revenue of $25.7M (+378.6% Y/Y) beats by $6.82M. • 2022 Financial Outlook: • TransMedics is updating full year 2022 revenue to be in the range of $80 million to $85 million vs $75.70M consensus, excluding the $1.4 million favorable change in estimate for contra revenue, which represents 164% to 181% growth compared to the company's prior year revenue. TransMedics' prior 2022 net revenue guidance was $67 million to $75 million.

TransMedics Reports Third Quarter 2022 Financial Results https://www.prnewswire.com/news-releases/transmedics-reports-third-quarter-2022-financial-results-301668313.html Net revenue of $25.7 million, comprised of $24.3 million in sales revenue and $1.4 million favorable adjustment 2022 Revenue Guidance Range Raised to $80 million to $85 million

Irgendwie schon 🙃